Activation of the Angiopoietin-Tie2 Pathway to Treat Ocular Hypertension and Glaucoma

点击翻译按钮获取中文摘要

 DESCRIPTION (provided by applicant): Glaucoma is a leading cause of blindness, afflicting more than 60 million people worldwide. Vision loss in glaucoma is due to progressive loss of retinal ganglion cells leading to deformation of the optic nerve. While the pathogenic events triggering the various forms of glaucoma remain obscure, increased intraocular pressure (IOP) due to impaired aqueous humor drainage has been identified as a major risk factor. Accordingly, current medical and surgical therapies are designed to promote fluid drainage from the anterior chamber to reduce ocular hypertension. While these therapies show some benefit, none are curative. The greatest obstacle to finding a cure has been a poor understanding of the molecular events leading to decreased aqueous humor drainage and retinal ganglion loss, preventing the development of therapies based on underlying disease mechanisms. We have shown that genetic disruption of the Angiopoietin-Tie2 signaling pathway in mice results in high IOP, bupthalmos and classic features of primary congenital glaucoma (PCG), a particularly devastating form of the disease in children that accounts for 5% of childhood blindness and 18% of blind-school registry. The primary defect in our mice is loss of Schlemm's canal and corneal limbal lymphatics resulting in defects of aqueous humor drainage. In 174 children with PCG, we have identified 10 mutations in the TIE2 gene and its ligand, Angiopoietin 1 (ANGPT1), suggesting this pathway plays a major role in human disease. In this proposal we will test the hypotheses that: 1) The development of the anterior angle of the eye including the outflow tract is dependent on the level of activity of the Tie2 receptor and reduced size and/or function of the draining vessels is sufficient to cause ocular hypertension, resulting in retinal ganglion cell los and glaucoma. 2) The TIE2 and ANGPT1 mutations observed in children with PCG reduce signaling function of the TIE2 receptor leading to alterations in Schlemm's canal and outflow of the anterior chamber. 3) Activation of TIE2 signaling within the corneal limbal region will enhance the size and function of Schlemm's canal, promoting aqueous humor drainage, reducing IOP and preventing retinal ganglion and vision loss. To test these hypotheses we have assembled a multidisciplinary team of ophthalmologists, vision scientists, geneticists, proteomics experts, vascular biologists and a number of unique reagents permitting us to determine: 1) the impact of a range of reductions in Angpt-Tie2 signaling on development of the irido-corneal angle, IOP and features of glaucoma in genetically engineered mice 2) how the TIE2 and ANGPT1 mutations in children with PCG affect activity of the receptor 3) whether activation of TIE2 using genetic or small molecule approaches rescues the glaucoma phenotype. Our studies provide an unprecedented opportunity to determine novel molecular mechanisms of glaucoma and ocular hypertension and an innovative approach to treat glaucoma and ocular hypertension through development of the first biologically-targeted therapy.